- Sales of Rs 990.8 crore and PAT of Rs 176 .8 crore for year ended June 30, 2021
- Sales for the quarter up by +40%
- The company has recorded a strong performance with sales of Rs 281 Crores in the Quarter ending June 30th, up by +40% Vs year ago in a tough environment backed by a sustained demand for our trusted quality vitamins, minerals and supplements.
- The company recorded sales of Rs 990.8 crore for the twelve-month fiscal year ending 30th June 2021. Results for the fiscal are not comparable Vs 1,329 Crore sales for the eighteen months period last year ending 30th June 2020. Profit After Tax (PAT) for the year ended 30th June 2021 is Rs 176.8 crores against Rs 254.08 crores in the previous 18 months fiscal year ended 30th June 2020.
Milind Thatte, Managing Director, Procter & Gamble Health Limited said, Given the uncertainty still presented by the pandemic, we continue to work towards protecting the health and safety of our employees and partners, ensuring uninterrupted supplies of our vitamins, minerals, supplements and medicinal products for our patients and consumers, and on supporting communities and relief efforts. As a part of the 'P& G Suraksha India' Covid-19 relief program, we contributed to the donation of 10 lakh vaccine doses for 5 lakh citizens in partnership with state governments and local authorities. We continue to invest in public health in India through flagship CSR program 'SEHAT' (meaning health). Under SEHAT, we recently announced a 3- year collaboration with Tata Trust for 'Yes To POSHAN', a new initiative which aims to advance the nutritional status of women and children at grassroots."